NasdaqGS - Delayed Quote USD

Blueprint Medicines Corporation (BPMC)

93.00 +2.27 (+2.50%)
At close: 4:00 PM EDT
93.00 0.00 (0.00%)
After hours: 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
249,380.00
249,380.00
204,036.00
180,080.00
793,735.00
Cost of Revenue
8,540.00
8,540.00
17,813.00
17,934.00
425.00
Gross Profit
240,840.00
240,840.00
186,223.00
162,146.00
793,310.00
Operating Expense
722,861.00
722,861.00
714,793.00
796,326.00
484,603.00
Operating Income
-482,021.00
-482,021.00
-528,570.00
-634,180.00
308,707.00
Net Non Operating Interest Income Expense
-18,793.00
-18,793.00
-16,767.00
2,386.00
6,599.00
Other Income Expense
-5,202.00
-5,202.00
-6,944.00
-9,290.00
-366.00
Pretax Income
-506,016.00
-506,016.00
-552,281.00
-641,084.00
314,940.00
Tax Provision
968.00
968.00
5,236.00
3,001.00
1,058.00
Net Income Common Stockholders
-506,984.00
-506,984.00
-557,517.00
-644,085.00
313,882.00
Diluted NI Available to Com Stockholders
-506,984.00
-506,984.00
-557,517.00
-644,085.00
313,882.00
Basic EPS
-9.20
-8.37
-9.35
-11.01
5.76
Diluted EPS
-9.20
-8.37
-9.35
-11.01
5.59
Basic Average Shares
60,302.75
60,558.00
59,642.00
58,518.00
54,534.00
Diluted Average Shares
60,302.75
60,558.00
59,642.00
58,518.00
56,168.00
Total Expenses
731,401.00
731,401.00
732,606.00
814,260.00
485,028.00
Net Income from Continuing & Discontinued Operation
-506,984.00
-506,984.00
-557,517.00
-644,085.00
313,882.00
Normalized Income
-506,984.00
-506,984.00
-557,517.00
-644,085.00
313,882.00
Net Interest Income
-18,793.00
-18,793.00
-16,767.00
2,386.00
6,599.00
EBIT
-482,021.00
-482,021.00
-528,570.00
-634,180.00
308,707.00
EBITDA
-470,356.00
-470,356.00
-516,835.00
-627,701.00
315,266.00
Reconciled Cost of Revenue
8,540.00
8,540.00
17,813.00
17,934.00
425.00
Reconciled Depreciation
11,665.00
11,665.00
11,735.00
6,479.00
6,559.00
Net Income from Continuing Operation Net Minority Interest
-506,984.00
-506,984.00
-557,517.00
-644,085.00
313,882.00
Normalized EBITDA
-470,356.00
-470,356.00
-516,835.00
-627,701.00
315,266.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 4/30/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
KRYS Krystal Biotech, Inc.
156.88
+0.77%
 
ARGX argenx SE
372.80
+1.14%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
RARE Ultragenyx Pharmaceutical Inc.
44.24
+0.89%
 
LEGN Legend Biotech Corporation
45.30
+1.98%
 
MRUS Merus N.V.
45.04
+0.24%
 
CRNX Crinetics Pharmaceuticals, Inc.
42.12
-0.40%
 
PCVX Vaxcyte, Inc.
60.72
+1.10%
 
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%